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Toll-like receptors (TLRs) are part of the innate immune system and can initiate an immune response upon exposure to harmful 
microorganisms. Neuronal TLRs are considered to be part of an established framework of interactions between the immune system 
and the nervous system, the major sensing systems in mammals. TLRs in the nervous system and neuronal TLRs are suspected 
to be important during inflammation and neurodegenerative diseases. The aim of this review is to offer an overview of the current 
knowledge about TLRs in neurodegenerative pathologies, with a focus on Parkinson’s disease. More research focusing on the role 
of TLRs in health and disease of the nervous system is needed and remains to be explored.
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INTRODUCTION
Publications were first selected about toll-like 
receptors (TLRs) on neurons, and on TLRs for which 
functional information in neurons was available. 
Publications were also selected for their focus on 
neurodegenerative diseases. The last literature search 
was performed on April 14th 2015. This review aims 
to offer an overview of the current knowledge about 
TLRs in the nervous system and to show the relevance 
of these receptors in neurodegenerative pathologies, 
with a focus on Parkinson’s disease (PD).
TLRs are the mammalian orthologue of Drosophila 
Melanogaster’s toll receptor discovered in 1988.[1] 
TLRs are part of the innate immune system and belong 
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to the pattern recognition receptors [Figure 1]. They 
can recognize both small molecular motifs conserved 
across microbes (pathogen-associated molecular 
pattern or PAMP) [Figure 2], and endogenous molecules 
generated during inflammation or tissue damage 
(damage associated molecular pattern or DAMP).[2-5] 
TLRs can initiate an acute inflammatory reaction 
and subsequently can coordinate the activation of the 
adaptive immune system. To date, thirteen TLRs are 
known, of which ten (TLR1-10) have been described 
in humans.[6] The cell surface TLRs recognize PAMPs 
that are mainly constituent of the bacterial cell wall 
or are expressed on the bacterial cell surface, such as 
lipopeptides and peptidoglycal (TLR1/TLR2, TLR2/
TLR6, TLR2/TLR10), lipopolysaccharide (LPS) (TLR4) 
and flagellin (TLR5). In contrast, the intracellular 
TLRs mainly recognize microbial nucleic acid 
including viral double-strand RNAs (TLR3), single-
strand RNAs (TLR7 and TLR8) and CpG ODN (TLR9).[7] 
TLRs can employ two second messenger pathways; 
the myeloid differentiation primary response gene 
88 (MyD88) pathway, activating nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB), or the TIR-
domain-containing adapter-inducing interferon-β 
(TRIF) pathway, activating interferon regulatory factor 
3 (IRF3) [Figure 2]. NF-κB controls DNA transcription 
resulting in the production of pro-inflammatory 
cytokines such as tumor necrosis factor α (TNFα), 
interleukin (IL)1β and IL6.[7,8] IRF3 is an interferon 
(IFN) regulatory factor leading to the production of 
antiviral type I IFN.[2,7]
The presence of TLRs on immune cells and epithelial 
cells is well known, but their expression is not restricted 
to these cell types. Glial cells and neurons express 
TLRs in both the peripheral nervous system (PNS) and 
the central nervous system (CNS) [Figure 3], allowing 
neurons to act as immune cells.[9-15] More specifically, 
in the CNS neurons, astrocytes and microglial cells 
express TLR1-9, whereas oligodendrocytes express 
only TLR2 and TLR3.[16-20] Peripheral neurons also 
express TLR1-9 and enteric glial cell express TLR1-
5, TLR7 and TLR9.[13,14,21-23] Neuronal TLR signaling 
pathways do not necessarily employ NF-κB[24-26] and 
may involve the glycogen synthase kinase 3β (GSK3β), 
jun-N-terminal kinase (JNK) and phosphatidylinositol 
3-kinase/protein kinase B (PI3K/AKT) pathways.[27-29] 
Interaction between neurons and the immune 
system has already been reported, setting the scene 
for neurons acting as immune cells.[30-34] It has been 
reported that neuronal TLRs are involved in the 
development and homeostasis of the nervous system, 
and notably in several neurodegenerative diseases.[35,36] 
Both TLR2 and TLR4 are involved in neuronal 
apoptosis, development and survival in the context 
Figure 1: Toll like receptors are part of the innate immune system and belong 
to the pattern recognition receptors
Figure 2: Different pathogens activate different TLRs. TLRs signal through 
two different pathways using myeloid differentiation primary response gene 
88 (MyD88) and TIR-domain-containing adapter-inducing interferon β, leading 
to activation of NF-kB and IRF respectively NF-kB leads to DNA transcription 
and cytokine production, while IRF leads to interferon production. TLRs: toll 
like receptors; NF-kB: nuclear factor κ-light-chain-enhancer of activated B 
cells; IRF: interferon regulatory factor
Figure 3: TLRs are differentially expressed by neurons and glial cells of the 
central, peripheral and enteric nervous system. TLRs: toll like receptors
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of opioids exposure, ischemia/stroke, viral infections 
and Alzheimer’s disease (AD),[28,29,37-43] via GSK3β and 
JNK.[28,29] TLR3 and TLR8 negatively regulate neuronal 
development and axonal growth and are involved in 
fighting viral infections,[9,16,24,25,27,44-46] through PI3K 
pathway.[27] Other information also indicates a role for 
TLRs in the nervous system during disease. TLR1-5, 
TLR8 and TLR9 are overexpreesed in PD and multiple 
systems atrophy (MSA) patients and in animal models 
of PD, AD, MSA and amyotrophic lateral sclerosis.[47-53] 
Of these receptors, TLR2 and TLR4 are of special 
interest in PD, as will become clear in the sections 
dedicated to these TLRs. The current knowledge 
about TLR2 and TLR4 in PD has focused heavily 
on microglia, and not so much on neuronal TLRs. 
To better understand the potential importance of 
neuronal TLRs in neurodegeneration and specifically 
in PD, AD and stroke the current knowledge about the 
function of neuronal TLRs in neuronal development 
and neurodegenerative diseases will be discussed here.
NERVOUS SYSTEM TLR EXPRESSION
This section will cover the expression of TLRs on 
neurons and glial cells [Figure 3]. To discuss the 
function of TLRs on neurons it is important to know 
whether neurons express TLRs. For the convenience 
of the reader, the information about expression has 
been organized based on location in the nervous 
system, and stage of life. To discuss the function of 
TLRs in the nervous system it is also necessary to first 
address whether glial cells express TLRs, because of 
their biological relevance for the functioning of the 
CNS and PNS.
Neuronal TLR expression
TLR expression on primary neurons has been found in 
several species, amongst which are humans,[10,12,13,15,16,45] 
mice,[13,14,26,28,43,54,55] and rats.[10,27,56,57] Neuronal TLRs 
are present in both parts of the nervous system; 
the CNS[12,26,28] and the PNS.[10,13,14,43,54,57] Expression 
of TLRs by neurons has been confirmed at mRNA 
level,[14,21,24,28,43] and protein level.[10,13,24,26,28,43,54,57,58] Most 
results on neuronal TLRs come from experiments in 
embryonic neurons because these are easier to culture 
than neurons from adult animals. Nonetheless, 
neurons express TLRs throughout life, starting at 
the embryonic stage,[14,24,26,28,43,58] followed by the 
postnatal,[54] and the young stages,[10,56] and finally in 
the adult stage of life.[10,12,13,21,58,55,57] Taken together, 
these data offer many opportunities to study neuronal 
TLRs for a wide range of research questions, since 
it is reported that TLRs are expressed throughout 
the nervous system and throughout the lifespan of 
animals.
TLR expression has also been found in several 
neuronal cell lines. The teratocarcinoma derived 
human post-mitotic dopaminergic neuronal cell line 
NT2-N expresses TLR3.[9,59-61] TLR3 is also expressed 
by human neuroblastoma cell lines (including 
noradrenergic cell lines, CHP-212 and SK-NSH; a 
noradrenergic and gamma-aminobutyric cell line, SH-
SY5Y; SH-SY5Y and a noradrenergic and dopaminergic 
cell line, BE(2)-C) and primary human neuroblastic 
cells.[27,44,45,59] The rat neuroblastoma cell line B103 
expresses TLR2.[38] The expression of TLR1-9 has been 
reported in the human CHP-212 neuroblastoma cell 
line.[16] Although cell lines are further removed from 
their original biological environment than primary 
cells, they do offer a more readily available source of 
material for further research towards understanding 
the functions of neuronal TLRs.
Glial TLR expression
The importance of glial TLRs in neurodegeneration 
is indisputable.[19,32,53,62-65] Glial cells come in many 
shapes and sizes, and have a critical role in the CNS 
and PNS, such as immune surveillance, the regulation 
of chemical environment and the production of 
the myelin sheath, which makes them biologically 
relevant to the functioning of neurons.
Glial cells are a heterogeneous group of cells all of 
them expressing TLRs. Microglia act as immune 
surveillance of the CNS and express TLR1-9 in 
both humans and mice.[19,20] Astrocytes regulate the 
chemical environment of neurons, and they express 
TLR1-9 in mice and TLR1, TLR3-5 and TLR9 in 
humans, while TLR2 and TLR6-8 were not detected 
in human astrocytes.[17,18] Oligodendrocytes and 
Schwann cells respectively produce the myelin sheath 
around neuronal axons in the CNS and PNS. Schwann 
cells express TLR1-9 in mice,[14,66] while only TLR2 
has been studied and detected in humans,[67] whereas 
TLR4 has been studied and detected in rats.[68,69] 
Human oligodendrocytes only express TLR2 and 
TLR3, while TLR1 and TLR4-9 were undetectable.[20] 
In glial cells of the enteric nervous system TLR2 -9 
have been found, while TLR1 is absent.[13,22,70]
NEURONAL TLR FUNCTIONALITY
Here we provide a comprehensive overview of the 
current knowledge about TLR functionality in the 
nervous system in relation to neurodegeneration. 
Specific information about neurons, microglia, and 
other cell types is included when appropriate.
TLR2
TLR2 is a TLR family member that is able to recognize 
bacterial lipopolypeptides and peptidoglycans. 
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TLR2 forms heterodimers with TLR1 and TLR6 and 
mediates the host response to Gram-positive bacteria 
and yeast infections via stimulation of NF-κB signaling 
pathway.[71] Recently, it has been demonstrated that 
TLR2 can also form a heterodimer with TLR10 acting 
as an inhibitory receptor with immune suppressing 
effects.[72]
PD
Clinical studies have shown that TLR2 expression 
is increased in PD. In particular, one study revealed 
specific increase in microglial TLR2 in the substantia 
nigra and the hippocampus in the early stages of 
the disease, but not during the late stages,[73] while 
another study showed an increase in TLR2 in the 
striatum of advanced PD patients.[74] These results 
indicate that expression of TLR2 in either early or 
advanced PD could be region-specific, and that TLR2 
is not necessarily expressed in all regions at the 
same time. The involvement of TLR2 in PD might be 
two-dimensional: microglial activation of TLR2 can 
induce neurotoxicity or TLR2 can be important for the 
clearance of α-synuclein, thus being neuroprotective.
In support of this function is the evidence that 
TLR2 polymorphism tends to be associated with an 
increased risk of PD. This polymorphism results in 
altered TLR2 promoter transcriptional activity leading 
to lower expression of TLR2.[75,76] Taken together, these 
findings are indirect indications of a possible role of 
TLR2 in the pathology of PD.
Overexpression of human α-synuclein in mice 
resulted in microglial activation and an increase 
in TLR2 expression.[74] Microglia seem to form a 
crucial link between TLR2 and PD pathology; an 
idea that is supported by results from cell culture 
studies: exposure to α-synuclein activates cultured 
microglia and increases their TLR2 expression;[49,77] 
it also changes the response of microglial cells to 
TLR1/2 stimulation by increasing their inflammatory 
response.[78]
It can be speculated that α-synuclein triggers 
neuroinflammation through microglial TLR2, 
initiating a positive feedback loop by increasing 
TLR2 expression on the microglia, resulting in 
neurodegeneration and disease progression. However, 
it is not yet clear why this process would be limited 
to the early disease stage in the substantia nigra 
and the hippocampus, while only occurring later in 
the striatum, or whether and how neuronal TLR2 
participates in this process.
AD
TLR2 expression was found on microglia surrounding 
amyloid β (Aβ) plaques in post-mortem brain sections 
and in an AD mouse model, raising the question 
whether and how TLR2 might be involved in AD 
pathology.[47,79] Injecting Aβ in the hippocampus of 
wild type (WT) mice increases TLR2 expression 
in microglia; Aβ protein was unable to induce a 
microglia-dependent inflammatory response in the 
cortex of TLR2 deficient mice.[80,81] The interaction 
between Aβ and TLR2 also affects behavior; TLR2 
deficient mice showed more pronounced cognitive 
impairments, which correlated with increased 
levels of Aβ protein.[81] It remains to be demonstrated 
whether there is a direct binding between TLR2 and 
the Aβ protein.
AD-related damage to neurons is at least partially 
dependent on microglial TLR2, since the effects of 
Aβ protein and TLR1/2 ligand on neuronal viability 
are additive and dependent on microglia, and the 
microglial inflammatory and phagocytic response 
to Aβ protein is TLR2-dependent.[80,82,83] Aβ protein- 
and TLR1/2 ligand-induced microglial-mediated 
neuronal death is likely conferred through the release 
of inflammatory mediators.[84] There is also indication 
for the involvement of neuronal TLR2 in AD. Neuronal 
TLR2 was upregulated when neuronal cultures were 
exposed to hydroxynonenal (HNE), an AD-related 
lipid peroxidation product, but not when exposed to Aβ 
protein.[40] HNE exposure also resulted in an increase 
in both phosphorylated JNK and cleaved caspase 3; 
however these effects were abolished by TLR4 knock-
out. Therefore, the functional consequence of TLR2 
upregulation in neurons by HNE is not yet known.
In summary, microglial TLR2 is key in the 
neuroinflammatory response of AD pathology, but 
is also responsible for the clearance of Aβ protein, 
while neuronal TLR2 might also play a part in this 
neuroinflammatory environment. So TLR2 can have 
either a beneficial or detrimental role in AD.
Stroke
Neuronal TLR2 was studied in the cerebral ischemia/
reperfusion (I/R) animal model of stroke. Cortical and 
hippocampal neurons of WT mice subjected to I/R 
injury showed transient TLR2 protein upregulation, 
although upregulation in the cortex may not have been 
exclusively neuronal.[29,37,39] TLR2-/- mice exposed to I/R 
showed less brain damage, smaller infarct volumes 
and less neurological deficits than WT mice, and TLR2-/- 
mice and mice treated with TLR2 antibody showed less 
inflammatory cell accumulation and reduced neuronal 
loss.[29,39,42] From a treatment perspective it is interesting 
that the anti-inflammatory agent baicalin, used for 
the treatment of stroke, reduced TLR2 expression in 
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hippocampal neurons after I/R injury.[37] However, 
before suggesting a potential role of TLR2 in the 
treatment of stroke, clinical studies are needed to 
determine whether TLR2 is viable as a marker or target 
for treatment in stroke.
Animal models show that TLR2 is relevant in 
relation to stroke, however, they might obscure the 
specific importance of neuronal TLR2 in the context 
of glial cells. In order to isolate and study neuronal 
TLR2 in a stroke model, cultured neurons were 
exposed to glucose deprivation, a model of stroke.[29] 
Increased cell death was found in WT neurons, while 
TLR2-/- neurons were resistant to glucose deprivation 
induced cell death. In a neuronal cell line oxygen-
glucose deprivation resulted in TLR2 upregulation 
and in an increase of non-apoptotic cell death.[85] 
These in vitro data confirm that stroke can result in 
neurodegeneration through the activation of neuronal 
TLR2, making neuronal TLR2 a potential player in 
brain damage after I/R injury in mice, independent 
from the influence of glial TLR2.
Information on TLR2 in the brain of patients with 
stroke is sorely missing and should be sought in 
future research, starting with investigating expression 
patterns in different brain regions. Also, a major focus 
of research should aim at distinguishing neuronal 
TLR2 from glial TLR2.
TLR3
TLR3 recognizes double stranded RNA associated with 
viral infection, and host RNA. Ligand binding induces 
the production of anti-viral mediators like the type I 
interferons (IFNs), such as IFN-α and -β production 
by leukocytes. These IFNs stimulate macrophages and 
natural killer cells to elicit an anti-viral response.[86]
TLR3 has not been studied in direct relationship 
to neurodegenerative diseases, but work has been 
performed on the effect of TLR3 in the development 
of the nervous system. TLR3 expression decreases 
in the embryonic CNS during neurogenesis.[58] 
Intrathecal injection of TLR3 agonist polyinosine: 
polycytidylic acid in postnatal day 4 mice resulted 
in sensory-motor deficits, neuroanatomical defects 
and fewer axons in the spinal cord, which was 
associated with neurodegeneration.[24] The role for 
TLR3 in this study was demonstrated by the fact that 
no anatomical or behavioral problems were found in 
TLR3-/- mice treated with polyinosine: polycytidylic 
acid.[24] It seems that TLR3 is involved in the proper 
development of the CNS in early fetal life, because 
the receptor is differentially expressed at different 
embryonic stages. After birth, stimulation of TLR3 
results in neurodegeneration. The decrease in 
expression of TLR3 during neurogenesis, as found in 
the embryonic brain, is also found in cultured neural 
progenitor cells (NPCs), making NPCs more sensitive 
to TLR3-mediated inhibition of proliferation than 
mature neurons.[58] Despite this reported decrease 
in TLR3 expression during neurogenesis, neurons 
do express functional TLR3.[24] In primary neurons, 
TLR3 stimulation inhibits neurite outgrowth and 
causes irreversible growth cone collapse, without 
affecting cell survival.[24] Different results were found 
in the high TLR3-expressing neuroblastoma cell line 
SK-N-AS, where exposure to a TLR3 ligand resulted 
in growth inhibition and apoptosis.[44] The difference 
in results on cell viability could be due to the use of 
different cell types (dorsal root ganglia,[24] NPCs,[58] and 
cell lines[44]), thus revealing the limits of cell culture 
as a model of biological processes.
Although all in vivo data are obtained from early 
life studies and interpretation of these data in the 
context of neurodegeneration must be done carefully, 
extrapolating these results leads to the hypothesis that 
stimulation of neuronal TLR3 could be detrimental in 
neurodegenerative diseases, especially in the context 
of viral infections. TLR3 is a viral sensing innate 
immune receptor. It is known that viral infections like 
influenza can cause neurodegeneration[87] and that 
viruses are linked to neurodegenerative diseases:[88] 
specifically hepatitis C virus, Eppstein-Barr virus 
and human immunodeficiency virus (HIV) have been 
associated with PD.[89-91] The involvement of neuronal 
TLRs during viral infections is discussed in more 
detail in a later part of this review.
TLR4
TLR4 detects LPS derived from Gram-negative bacteria 
and host-derived signaling molecules such as heat 
shock proteins, and extracellular matrix proteins, 
after which the innate immune system is activated, 
leading to an inflammatory response.[92-94]
PD
The expression of TLR4 is increased in PD and MSA 
post-mortem brain tissue, suggesting clinical relevance 
to TLR4 in PD and neurodegeneration in general.[50,74] 
Animal experiments have been used to further 
elucidate the role of TLR4 in PD. TLR4-/- mice were more 
vulnerable to dopaminergic neuronal loss and motor 
problems induced by α-synuclein overexpression, but 
less vulnerable to the induction of PD symptoms by 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
treatment.[95,96] Furthermore, TLR4 and α-synuclein 
are both necessary for LPS-induced neurodegeneration 
in mice.[97,98] Therefore, mouse models support the 
importance of TLR4 in PD, but make no suggestion 
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as to the impact of TLR4 on disease development, 
since TLR4 was both protective and harmful in these 
models. Since TLR4 is suggested to be protective in 
the context of α-synuclein overexpression, TLR4 
seems likely to be protective in the context of PD, 
since α-synuclein misfolding and aggregation is a 
hallmark of the disease. The harmful contribution 
of TLR4 to MPTP-induced PD seems to suggest that 
TLR4 might have a negative impact on the health 
of a subgroup of PD patients who suffer from toxin-
induced PD (for instance after exposure to MPTP or 
rotenone). Therefore, TLR4 appears mostly protective 
in the context of PD, but it might be harmful in the 
context of toxin-induced PD.
Similar to TLR2, microglia form a link between TLR4 
and PD. Microglia are necessary for LPS-induced 
degeneration of rat cortical neurons in cell culture 
since these neurons themselves do not express 
TLR4, and nitric oxide and superoxide seem to be 
at least partially responsible for microglial-induced 
neurodegeneration.[97,98] On the other hand, microglial 
TLR4 is necessary for the neuroprotective endocytosis 
of α-synuclein.[96] Microglia activated with α-synuclein 
downregulate TLR4, disabling any neuroinflammatory 
positive feedback loop, but also reducing the ability 
of the microglia to take up α-synuclein from their 
environment.[77] These results are contradictive and 
whether TLR4 is protective or injurious in PD is still a 
matter of debate. The balance between the contribution 
of microglial TLR4 to neuroinflammation and the 
endocytosis of α-synuclein might eventually determine 
whether this receptor is protective or harmful to the 
surrounding neurons. TLR4 is a promising target 
for future PD research. The role of TLR4 during PD 
can be both beneficial and harmful, and the factors 
determining the outcome need to be investigated 
in more detail. It seems that neuronal TLR4 could 
be protective, but the role of microglial TLR4 is still 
not fully understood. Resolving this debate could 
potentially lead to approaches aimed at turning 
harmful TLR4 responses into protective ones.
AD
One of the first lines of evidence suggesting that TLR4 
might be involved in AD pathology comes from two 
studies where a TLR4 polymorphism was found to 
be protective against late onset Alzheimer’s disease 
in the Italian population and glial cells surrounding 
Aβ plaques showed increased TLR4 expression in 
post mortem brain tissue.[99,100] In a genetic AD mouse 
model TLR4 knock-out reduced the expression of 
TNFα and chemokine (C-C motif) ligand 4 (also known 
as macrophage inflammatory protein-1β) in cortex 
homogenate, while increasing the amount of activated 
microglia, activated astrocytes, and Aβ protein in the 
brain.[101,102] Effects of TLR4 knock-out on behavior 
or disease progression have not been reported. The 
increase of Aβ protein in the brain of TLR4-/- animals 
could be due to a lack of TLR4-mediated Aβ clearance, 
potentially by microglia.[102,103]
Cell culture data support a pro-inflammatory role 
for microglia, and implicate microglia-induced 
inflammation in neuronal degeneration. Mouse 
microglia initiate an inflammatory and phagocytic 
response to aggregated Aβ through TLR4, resulting 
in microglia-mediated neuronal death.[82,99] Microglia 
need TLR4 to initiate LPS-stimulated Aβ uptake, in 
fact they trigger a stronger inflammatory response to 
Aβ in combination with LPS.[84,102]
Neurons themselves respond to Aβ and AD-related 
peroxidation product HNE through TLR4, resulting 
in apoptosis.[40] Since little is known about the 
role of neuronal TLR4 in AD, it is important to 
start exploring the function of this receptor in 
animal models and in patient tissue, in a way that 
differentiates glial-mediated TLR4 responses from 
neuronal responses, for instance by selective knock-
down of TLR4 in neurons in AD mouse models. 
Collectively, it seems that TLR4 induces an immune 
response in AD through pro-inflammatory cytokines, 
aimed at the removal of Aβ by microglial uptake, 
but also phagocytosis of neurons by microglia. 
Insufficient removal of Aβ results in an increase of Aβ 
in the extracellular space, the subsequent activation 
of microglia and astrocytes, and neuronal apoptosis. 
In light of this hypothesis, it is also interesting to note 
the similarity in the role of microglial TLR4 in AD and 
PD, where this receptor is responsible for the uptake 
of disease-specific aggregated protein and initiation of 
neuroinflammation, possibly causing neuronal death.
Stroke
TLR4 has both beneficial and detrimental effects in 
stroke models. Neurons of I/R treated mice show TLR4 
upregulation, a first clue that TLR4 is involved in stroke-
induced brain damage.[29,37] Paradoxically, mice treated 
with low dose systemic LPS two days before I/R injury 
had smaller infarct sizes and less neuroinflammation 
in the brain, while TLR4-/- mice had less stroke-induced 
brain damage and less neurological deficits after I/R 
treatment.[29,104] Although these results do not suggest a 
beneficial or harmful role of TLR4 in stroke, the data are 
not mutually exclusive. TLR4 stimulation before stroke 
seems to be protective, while TLR4 stimulation during 
stroke seems detrimental. This hypothesis is supported 
by in vitro experiments. Increased TLR4 activity does 
not increase neuronal death, and TLR4 stimulation 
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can be beneficial to neuronal survival at low concentra
tions.[43,105,54,106] On the other hand, glucose deprivation 
increased TLR4 expression and cell death in neuronal 
cultures while TLR4-/- neurons were less susceptible to 
glucose deprivation induced cell death.[29,37] In agreement 
with the in vivo results, it seems that TLR4 stimulation 
per se is not harmful to neurons and it might even be 
beneficial. During stroke TLR4 has a negative impact 
on neuronal survival, possibly in part through glucose 
deprivation, but most likely also as the result of a more 
profound inflammatory process.[107] In relation to the 
opposing effects of TLR4 in PD, it is curious that TLR4 
can have either protective or detrimental effects in the 
context of stroke.
TLR8
In innate immune cells TLR8 functions as an 
endosomal receptor that recognizes viral single-
stranded RNA. Stimulation of TLR8 induces the 
activation of the My88 signaling pathway leading to 
an anti-viral response.[108]
The role of TLR8 in PD and AD has not yet been studied 
in detail, and is therefore unknown. In stroke patients a 
higher level of TLR8 mRNA expression in whole blood 
sample was positively correlated with poor patient 
outcome after three months, larger infarct volume 
and greater inflammatory response.[109] Similar results 
were found in a mouse stroke model: diseased animals 
had increased TLR8 mRNA expression in their brain 
and systemic administration of a TLR8 agonist before 
ischemic insult increased infarct size and neurological 
problems.[110] The neuronal damage in stroke patients 
and mice could be mediated by neuronal TLR8, since 
TLR8 stimulation of neurons results in fewer and shorter 
neurites and apoptosis and slightly but significantly 
increases oxygen-glucose deprivation induced cell 
death, while TLR8 silencing reduced oxygen-glucose 
deprivation induced cell death.[26,110] Interestingly, 
neurodevelopmental research has shown that TLR8 
is differentially expressed in the embryonic and 
postnatal brain in mice.[25,26] In the mouse brain TLR8 
expression increases between embryonic day 12 and 
postnatal day 1, and decreases between postnatal day 7 
and adulthood.[26] During early embryonic development 
TLR8 expression is high in postmitotic migrating 
cells, but not in the periventricular proliferative 
area.[26] During late embryonic development, TLR8 
was restricted to axonal tracts (including the olfactory 
nerve fiber layer, cortical intermediate zone, internal 
capsule, anterior commissure, fimbria of hippocampus 
and optic chiasm).[26] Postnatal expression is diffuse 
throughout the brain and located in soma.[26] This 
indicates a potential role of TLR8 in brain development. 
Considering how little is known about its function in 
the nervous system, specifically on neurons, both the 
fields of neurodevelopment and neurodegeneration 
have much to explore with regards to TLR8. This TLR 
could be considered critical to study the role of TLRs 
on neurons in neurodegeneration, and PD in particular.
NEURONAL TLRS AND VIRAL INFECTIONS
In the previous sections we have discussed that 
TLRs play an important role in microglial-mediated 
neuroinflammation of neurodegenerative diseases. 
In this context it is extremely relevant to investigate 
further the TLR-induced immune-like functions of 
neurons and to understand the role of neurons in 
neuroinflammation. Viral infections offer useful 
conditions to study TLR-mediated neuronal immune 
functions, because neurons respond to viral infections 
by upregulating TLR and secreting IFN.
Neurons upregulate TLR3 and TLR4 mRNA in 
response to HIV and adenovirus infection, they also 
upregulate IFN-β mRNA in response to Sendai virus, 
and increase IFN production after TLR3 and TLR8 
stimulation.[16,27,45,111] TLR3 and TLR8 are virus-sensing 
receptors and virus-infected cells use IFNs to signals 
to the neighboring cells that an infection is ongoing 
and to induce an immune response from nearby 
immune cells (or glial cells). All together, such findings 
suggest that neurons can act as immune cells. These 
neuronal TLR-mediated immune responses seem to be 
protective to the neurons themselves. Stimulation of 
TLR3 on neuronal cell lines inhibits HIV replication 
through IFN-λ, and TLR3 and TLR8 stimulation of 
a neuronal cell line results in lower susceptibility to 
herpes simplex virus-1 potentially through IFN-α. 
Moreover, TLR3-/- primary neurons showed increased 
infection when exposed to West Nile virus compared to 
WT neurons which was not due to changes in IFN-α of 
IFN-β production.[16,45,46] The protective effect of TLR3 
during viral infection of the CNS has been confirmed 
in mice: infection of TLR3-/- mice with West Nile virus 
resulted in a higher viral burden in neurons and 
increased mortality compared to WT mice.[46] The viral-
sensing receptors TLR3 and TLR8 are able to initiate a 
protective immune-like response in neurons upon viral 
challenge. Unfortunately, it is not clear whether TLR2 
or TLR4 have a similar potential to protect neurons 
against pathogenic (bacterial) attack, and what the 
resulting immune response would be. Therefore, it 
is interesting to investigate a wide range of possible 
immune-like responses in neuronal cultures exposed 
to endogenous and exogenous TLR2 and TLR4 stimuli.
CONCLUSION
This review summarizes the relevance of TLRs in the 
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nervous system, and especially in neurodegenerative 
pathologies. Current literature shows that several 
neuronal TLRs are involved in the development of the 
nervous system and in neurodegenerative diseases. 
Neuronal TLRs are important for NPC proliferation, 
axonal growth, cell survival and in defense against 
viral infections. The capacity of TLR-stimulated 
neurons to respond as immune-like cells (production 
of cytokines and induction of apoptosis) is of special 
interest for neurodegenerative diseases, since 
microglial-mediated neuroinflammation is a feature 
of neurodegenerative diseases. These results raise 
the question whether neurons are active contributing 
to neuroinflammatory degenerative process such as 
PD. TLR2, TLR3, TLR4 and TLR8 are all important 
for neuronal function and are implicated in PD, AD 
and stroke. This suggests that these TLRs should be 
investigated further in PD and other diseases as the 
first innate immune receptors on neurons.
Neuronal TLR2 has divergent functions in the nervous 
system. It responds to tissue damage during stroke, and 
allows neurons to respond to the neuroinflammatory 
environment of AD pathology. It is interesting 
to analyze the involvement of neuronal TLR2 in 
neurodegenerative diseases other than stroke and AD. 
Elucidating the role of neuronal TLR2 in PD is very 
attractive, since microglial TLR2 has already been 
described in PD pathology.[49,73,77,78] We hypothesize 
that α-synuclein triggers neuroinflammation through 
microglial TLR2, initiating a positive feedback loop by 
increasing TLR2 expression on the microglia, resulting 
in neurodegeneration and disease progression. The 
contribution of neuronal TLR2 in this process is yet 
unknown, and could be evaluated by studying PD 
mouse models with a specific knock-out of TLR2 in 
neurons, and by studying the immune response of 
neurons activated with TLR2 stimuli in culture.
Neuronal TLR3 regulates cortical development 
and neurogenesis and is able to initiate immune-
like responses in response to viral infections. This 
provides an interesting perspective to explore the 
function of neuronal TLR3 in neurodegenerative 
diseases, since we hypothesize that neuronal TLR3 
will be detrimental in this context, and because viral 
infections could cause PD through the development 
of encephalopathy.[112] Expression patterns of TLR3 
in brain tissue of early and late PD would shed light 
on whether TLR3 is indeed an interesting candidate 
for future PD research, and what role neuronal TLR3 
might play in disease development.
TLR4 is a very promising target for future PD research. 
The effect of TLR4 during PD can be both beneficial and 
harmful, but the factors determining the outcome are yet 
unknown. It is conceivable that neuronal TLR4 could 
be protective, but the role of microglial TLR4 is still in 
uncertain. One explanation for the confounding function 
of TLR4 in PD needs to be sought in the interaction 
between TLR4 stimulation and the stimulation of 
other receptors. Such interactions are known to occur 
for TLR4, in fact neuronal TLR4 interacts with the 
transient receptor potential cation channel V1 receptor 
to transduce itch signals and possibly to transduce pain 
caused by bacterial infections.[55,113] These data open up 
a new scenario of research in PD, particularly using 
specific neuronal TLR4 deficient animals, especially if 
this knock-out can be initiated before, during and after 
PD initiation, since the beneficial or detrimental effects 
of TLR4 in stroke seem to be dependent on the timing of 
TLR4 stimulation in relation to stroke. Similarly, the study 
of the effects of TLR4 stimulation in neuronal cultures in 
combination with (microglial) immune signals known 
to be important in PD pathology represents also another 
research direction.
TLR8 influences neuronal growth and survival and 
is also important for the initiation of the immune 
response during neuronal viral infections. The 
implications for neurodegenerative diseases are 
manifold, since viral infections have been linked to 
PD and a better understanding of the mechanisms 
underlying neuronal survival could help to reduce 
neuronal death.[112] Since so little is known about TLR8, 
further investigation about the role of this receptor 
represents an opportunity for future PD research. 
Neuronal TLRs are an emerging research area, which 
will have implications for neurodevelopmental, 
neurodegenerative and neuroinflammatory research. To 
date neuronal TLR2-4 and neuronal TLR8 are known to 
be promising candidates for future studies. Elucidation 
of the function of other neuronal TLRs requires further 
research that would lead to a better understanding of the 
interaction between the nervous system and the immune 
system.
Financial support and sponsorship
This review was supported by Utrecht University 
Focus & Mass Program Drug Innovation Exploring 
neuro-immunomodulatory targets for drugs and 
medical food concepts in CNS disorders and chronic 
inflammatory intestinal diseases.
Conflicts of interest
J. Garssen is employee at Nutricia research, Utrecht, 
the Netherlands.
REFERENCES
1.  Hashimoto C, Hudson KL, Anderson KV. The Toll gene of 
35Neuroimmunol Neuroinflammation | Volume 3 | Issue 2 | February 15, 2016
Drosophila, required for dorsal-ventral embryonic polarity, appears 
to encode a transmembrane protein. Cell 1988;52:269-79.
2.  Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate 
immunity. Cell 2006;124:783-801.
3.  Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13:816-25.
4.  Kumar H, Kawai T, Akira S. Pathogen recognition in the innate 
immune response. Biochem J 2009;420:1-16.
5.  Wagner H. Endogenous TLR ligands and autoimmunity. Adv 
Immunol 2006;91:159-73.
6.  Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, 
Giese T, Endres S, Hartmann G. Quantitative expression of toll-like 
receptor 1-10 mRNA in cellular subsets of human peripheral blood 
mononuclear cells and sensitivity to CpG oligodeoxynucleotides. 
J Immunol 2002;168:4531-7.
7.  Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front 
Immunol 2014;5:461.
8.  Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory 
diseases. J Clin Invest 2001;107:7-11.
9.  Prehaud C, Megret F, Lafage M, Lafon M. Virus infection switches 
TLR-3-positive human neurons to become strong producers of 
beta interferon. J Virol 2005;79:12893-904.
10.  Wadachi R, Hargreaves KM. Trigeminal nociceptors express TLR-
4 and CD14: a mechanism for pain due to infection. J Dent Res 
2006;85:49-53.
11.  Lafon M, Megret F, Lafage M, Prehaud C. The innate immune 
facet of brain: human neurons express TLR-3 and sense viral 
dsRNA. J Mol Neurosci 2006;29:185-194.
12.  Jackson AC, Rossiter JP, Lafon M. Expression of Toll-like receptor 3 
in the human cerebellar cortex in rabies, herpes simplex encephalitis, 
and other neurological diseases. J Neurovirol 2006;12:229-34.
13.  Barajon I, Serrao G, Arnaboldi F, Opizzi E, Ripamonti G, Balsari 
A, Rumio C. Toll-like receptors 3, 4, and 7 are expressed in the 
enteric nervous system and dorsal root ganglia. J Histochem 
Cytochem 2009;57:1013-23.
14.  Goethals S, Ydens E, Timmerman V, Janssens S. Toll-like receptor 
expression in the peripheral nerve. Glia 2010;58:1701-9.
15.  Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, 
Arnold MM, Knipe DM, Finberg RW. Herpes simplex virus 1 
interaction with Toll-like receptor 2 contributes to lethal encephalitis. 
Proc Natl Acad Sci U S A 2004;101:1315-20.
16.  Zhou Y, Ye L, Wan Q, Zhou L, Wang X, Li J, Hu S, Zhou D, Ho 
W. Activation of Toll-like receptors inhibits herpes simplex virus-1 
infection of human neuronal cells. J Neurosci Res 2009;87:2916-25.
17.  McKimmie CS, Fazakerley JK. In response to pathogens, glial 
cells dynamically and differentially regulate Toll-like receptor gene 
expression. J Neuroimmunol 2005;169:116-25.
18.  Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, 
Shapiro A, Antel JP. TLR signaling tailors innate immune responses 
in human microglia and astrocytes. J Immunol 2005;175:4320-30.
19.  Olson JK, Miller SD. Microglia initiate central nervous system 
innate and adaptive immune responses through multiple TLRs. J 
Immunol 2004;1733916-24.
20.  Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-
like receptors in the human central nervous system. J Neuropathol 
Exp Neurol 2002;61:1013-021.
21.  Ochoa-Cortes F, Ramos Lomas T, Miranda-Morales M, 
Spreadbury I, Ibeakanma C, Barajas-Lopez C, Vanner S. Bacterial 
Cell Products Signal to Mouse Colonic Nociceptive Dorsal Root 
Ganglia Neurons. Am J Physiol liver Physiol 2010;299:G723-32.
22.  Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, 
Cuomo R, Sarnelli G, Steardo L1. Palmitoylethanolamide improves 
colon inflammation through an enteric glia/toll like receptor 
4-dependent PPAR-alpha activation. Gut 2014;63:1300-12.
23.  Turco F, Sarnelli G, Cirillo C, Palumbo I, De Giorgi F, D’Alessandro 
A, Cammarota M, Giuliano M, Cuomo R. Enteroglial-derived 
S100B protein integrates bacteria-induced Toll-like receptor 
signalling in human enteric glial cells. Gut 2014;63:105-15.
24.  Cameron JS, Alexopoulou L, Sloane JA, DiBernardo AB, Ma 
Y, Kosaras B, Flavell R, Strittmatter SM, Volpe J, Sidman R, 
Vartanian T. Toll-like receptor 3 is a potent negative regulator of 
axonal growth in mammals. J Neurosci 2007;27:13033-41.
25.  Ma Y, Haynes RL, Sidman RL, Vartanian T. TLR8: an innate immune 
receptor in brain, neurons and axons. Cell Cycle 2007;6:2859-68.
26.  Ma Y, Li J, Chiu I, Wang Y, Sloane JA, Lü J, Kosaras B, Sidman 
RL, Volpe JJ, Vartanian T. Toll-like receptor 8 functions as a 
negative regulator of neurite outgrowth and inducer of neuronal 
apoptosis. J Cell Biol 2006;175:209-15.
27.  Peltier DC, Simms A, Farmer JR, Miller DJ. Human neuronal cells 
possess functional cytoplasmic and TLR-mediated innate immune 
pathways influenced by phosphatidylinositol-3 kinase signaling. J 
Immunol 2010;184:7010-21.
28.  Li Y, Li H, Zhang Y, Sun X, Hanley GA, LeSage G, Zhang Y, 
Sun S, Peng Y, Yin D. Toll-like receptor 2 is required for opioids-
induced neuronal apoptosis. Biochem Biophys Res Commun 
2010;391:426-30.
29.  Tang SC, Arumugam T V, Xu X, Cheng A, Mughal MR,  Pivotal 
role for neuronal Toll-like receptors in ischemic brain injury and 
functional deficits. Proc Natl Acad Sci U S A 2007;104:13798-803.
30.  van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp 
FP, Bienenstock J. Functional expression of neurokinin 1 receptors 
on mast cells induced by IL-4 and stem cell factor. J Immunol 
2003;171:2074-9.
31.  Rijnierse A, Kroese AB, Redegeld FA, Blokhuis BR, van der 
Heijden MW, Koster AS, Timmermans JP, Nijkamp FP, Kraneveld 
AD. Immunoglobulin-free light chains mediate antigen-specific 
responses of murine dorsal root ganglion neurons. J Neuroimmunol 
2009;208:80-86.
32.  Downes CE, Crack PJ. Neural injury following stroke: are Toll-like 
receptors the link between the immune system and the CNS? Br J 
Pharmacol 2010;160:1872-88.
33.  Snoek SA, Verstege MI, Boeckxstaens GE, van den Wijngaard 
RM, de Jonge WJ. The enteric nervous system as a regulator of 
intestinal epithelial barrier function in health and disease. Expert 
Rev Gastroenterol Hepatol 2010;4:637-51.
34.  Wood JD. Visceral pain: spinal afferents, enteric mast cells, enteric 
nervous system and stress. Curr Ph Des 2011;17(16):1573-5.
35.  Trudler D, Farfara D, Frenkel D. Toll-like receptors expression and 
signaling in glia cells in neuro-amyloidogenic diseases: towards future 
therapeutic application. Mediators Inflamm 2010; pii: 497987
36.  Drouin-Ouellet J, Cicchetti F. Inflammation and neurodegeneration: 
the story “retolled.” Trends Pharmacol Sci 2012;33:542-51.
37.  Li HY, Yuan ZY, Wang YG, Wan HJ, Hu J, Chai YS, Lei F, Xing 
DM, DU LJ. Role of baicalin in regulating Toll-like receptor 2/4 after 
ischemic neuronal injury. Chin Med J (Engl) 2012;125:1586-93.
38.  Paulino AD, Ubhi K, Rockenstein E, Adame A, Crews L, Letendre 
S, Ellis R, Everall IP, Grant I, Masliah E. Neurotoxic effects of the 
HCV core protein are mediated by sustained activation of ERK via 
TLR2 signaling. J Neurovirol 2011;17327-340.
39.  Ziegler G, Harhausen D, Schepers C, Hoffmann O, Röhr C, Prinz 
V, König J, Lehrach H, Nietfeld W, Trendelenburg G. TLR2 has 
a detrimental role in mouse transient focal cerebral ischemia. 
Biochem Biophys Res Commun 2007;359:574-9.
40.  Tang SC, Lathia JD, Selvaraj PK, Hoffmann O, Röhr C, Prinz 
V, König J, Lehrach H, Nietfeld W, Trendelenburg G. Toll-like 
receptor-4 mediates neuronal apoptosis induced by amyloid 
beta-peptide and the membrane lipid peroxidation product 
4-hydroxynonenal. Exp Neurol 2008;213:114-21.
41.  Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch 
JH, Williams DL, Li C. Differential roles of TLR2 and TLR4 in 
acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 
2009;1262:100-108.
42.  Ziegler G, Freyer D, Harhausen D, Khojasteh U, Nietfeld W, 
Trendelenburg G. Blocking TLR2 in vivo protects against accumulation 
of inflammatory cells and neuronal injury in experimental stroke. J 
Cereb Blood Flow Metab 2011;31:757-66.
43.  Anitha M, Vijay-Kumar M, Sitaraman S V, Gewirtz AT, Srinivasan S. 
Gut microbial products regulate murine gastrointestinal motility via 
Toll-like Receptor 4 signaling. Gastroenterology 2012;143:1006-16.
44.  Chuang JH, Chuang HC, Huang CC, Wu CL, Du YY, Kung 
ML, Chen CH, Chen SC, Tai MH. Differential toll-like receptor 
3 (TLR3) expression and apoptotic response to TLR3 agonist in 
human neuroblastoma cells. J Biomed Sci 2011;18:65.
45.  Zhou L, Wang X, Wang YJ, Activation of toll-like receptor-3 induces 
interferon-lambda expression in human neuronal cells. Activation 
of toll-like receptor-3 induces interferon-lambda expression in 
human neuronal cells. Neuroscience 2009;159:629-37.
46.  Daffis S, Samuel MA, Suthar MS, Gale Jr M, Diamond MS. 
Toll-like receptor 3 has a protective role against West Nile virus 
infection. J Virol 2008;82:10349-58.
47.  Letiembre M, Liu Y, Walter S, Hao W, Pfander T, Wrede A, Schulz-
Schaeffer W, Fassbender K. Screening of innate immune receptors 
in neurodegenerative diseases: a similar pattern. Neurobiol Aging 
Neuroimmunol Neuroinflammation |  Volume 3 | Issue 2 | February 15, 2016  36
2009;30:759-68.
48.  Ros-Bernal F, Hunot S, Herrero MT, Microglial glucocorticoid receptors 
play a pivotal role in regulating dopaminergic neurodegeneration in 
parkinsonism. Microglial glucocorticoid receptors play a pivotal role 
in regulating dopaminergic neurodegeneration in parkinsonism. Proc 
Natl Acad Sci U S A 2011;108:6632-7.
49.  Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong Lee S, 
Masliah E, Hwang D, Lee HJ, Lee SJ. Neuron-released oligomeric 
alpha-synuclein is an endogenous agonist of TLR2 for paracrine 
activation of microglia. Nat Commun 2013;4:1562.
50.  Stefanova N, Reindl M, Neumann M, Kahle PJ, Poewe W, Wenning 
GK. Microglial activation mediates neurodegeneration related to 
oligodendroglial alpha-synucleinopathy: implications for multiple 
system atrophy. Mov Disord 2007;22:2196-203.
51.  Brudek T, Winge K, Agander TK, Pakkenberg B. Screening of 
Toll-like receptors expression in multiple system atrophy brains. 
Neurochem Res 2013;38:1252-9.
52.  Panaro MA, Lofrumento DD, Saponaro C, De Nuccio F, Cianciulli A, 
Mitolo V, Nicolardi G. Expression of TLR4 and CD14 in the central 
nervous system (CNS) in a MPTP mouse model of Parkinson’s-like 
disease. Immunopharmacol Immtoxicol 2008;30:729-40.
53.  Landreth GE, Reed-Geaghan EG. Toll-like receptors in Alzheimer’s 
disease. Curr Top Microbiol Immunol 2009;336:137-53.
54.  Kunda PE, Cavicchia JC, Acosta CG. Lipopolysaccharides and 
trophic factors regulate the LPS receptor complex in nodose and 
trigeminal neurons. Neuroscience 2014;280:60-72.
55.  Min H, Lee H, Lim H, Jang YH, Chung SJ, Lee CJ, Lee SJ. TLR4 
enhances histamine-mediated pruritus by potentiating TRPV1 
activity. Mol Brain 2014;7:59.
56.  Maslinska D, Laure-Kamionowska M, Maslinski S. Toll-like 
receptors in rat brains injured by hypoxic-ischaemia or exposed to 
staphylococcal alpha-toxin. Folia Neuropathol 2004;42:125-32.
57.  Arciszewski MB, Sand E, Ekblad E. Vasoactive intestinal peptide 
rescues cultured rat myenteric neurons from lipopolysaccharide 
induced cell death. Regul Pept 2008;146:218-223.
58.  Lathia JD, Okun E, Tang SC, Griffioen K, Cheng A, Mughal MR, 
Laryea G, Selvaraj PK, ffrench-Constant C, Magnus T, Arumugam TV, 
Mattson MP. Toll-like receptor 3 is a negative regulator of embryonic 
neural progenitor cell proliferation. J Neurosci 2008;28:13978-84.
59.  Menager P, Roux P, Megret F, Bourgeois JP, Le Sourd AM, 
Danckaert A, Lafage M, Préhaud C, Lafon M. Toll-like receptor 
3 (TLR3) plays a major role in the formation of rabies virus Negri 
Bodies. PLoS Pathog 2009;5:e1000315.
60.  Pleasure SJ, Page C, Lee VM. Pure, postmitotic, polarized 
human neurons derived from NTera 2 cells provide a system 
for expressing exogenous proteins in terminally differentiated 
neurons. J Neurosci 1992;12:1802-15.
61.  Schwartz CM, Spivak CE, Baker SC, McDaniel TK, Loring JF, 
Nguyen C, Chrest FJ, Wersto R, Arenas E, Zeng X, Freed WJ, Rao 
MS. NTera2: a model system to study dopaminergic differentiation 
of human embryonic stem cells. Stem Cells Dev 2005;14:517-34.
62.  Lee H, Lee S, Cho IH, Lee SJ. Toll-like receptors: sensor molecules 
for detecting damage to the nervous system. Curr Protein Pept Sci 
2013;14:33-42.
63.  Carpentier PA, Duncan DS, Miller SD. Glial toll-like receptor 
signaling in central nervous system infection and autoimmunity. 
Brain Behav Immun 2008;22:140-47.
64.  Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in 
defense and damage of the central nervous system. J Neuroimmune 
Pharmacol 2007;2:297-312.
65.  Lehnardt S. Innate immunity and neuroinflammation in the CNS: 
the role of microglia in Toll-like receptor-mediated neuronal injury. 
Glia 2010;58:253-263.
66.  Lee H, Jo EK, Choi SY, Oh SB, Park K, Kim JS, Lee SJ. Necrotic 
neuronal cells induce inflammatory Schwann cell activation via 
TLR2 and TLR3: implication in Wallerian degeneration. Biochem 
Biophys Res Commun 2006;350:742-7.
67.  Oliveira RB, Ochoa MT, Sieling PA, Rea TH, Rambukkana A, 
Sarno EN, Modlin RL. Expression of Toll-like receptor 2 on human 
Schwann cells: a mechanism of nerve damage in leprosy. Infect 
Immun 2003;71:1427-33.
68.  Lee H, Park C, Cho IH, Kim HY, Jo EK, Lee S, Kho HS, Choi SY, 
Oh SB, Park K, Kim JS, Lee SJ. Double-stranded RNA induces 
iNOS gene expression in Schwann cells, sensory neuronal death, 
and peripheral nerve demyelination. Glia 2007;55:712-22.
69.  Cheng C, Qin Y, Shao X, Wang H, Gao Y, Cheng M, Shen A. 
Induction of TNF-alpha by LPS in Schwann cell is regulated by 
MAPK activation signals. Cell Mol Neurobiol 2007;27:909-21.
70.  Brun P, Gobbo S, Caputi V, Spagnol L, Schirato G, Pasqualin M, 
Levorato E, Palù G, Giron MC, Castagliuolo I. Toll like receptor-2 
regulates production of glial-derived neurotrophic factors in murine 
intestinal smooth muscle cells. Mol Cell Neurosci 2015;68:24-35.
71.  van Bergenhenegouwen J, Plantinga TS, Joosten LA, Netea MG, 
Folkerts G, Kraneveld AD, Garssen J, Vos AP. TLR2 & Co: a 
critical analysis of the complex interactions between TLR2 and 
coreceptors. J Leukoc Biol 2013;94:885-902.
72.  Oosting M, Cheng S-C, Bolscher JM, Vestering-Stenger R, Plantinga 
TS, Verschueren IC, Arts P, Garritsen A, van Eenennaam H, Sturm 
P, Kullberg BJ, Hoischen A, Adema GJ, van der Meer JW, Netea 
MG, Joosten LA. Human TLR10 is an anti-inflammatory pattern-
recognition receptor. Proc Natl Acad Sci U S A 2014;111:E4478-84.
73.  Doorn KJ, Moors T, Drukarch B, van de Berg WD, Lucassen PJ, 
van Dam AM. Microglial phenotypes and toll-like receptor 2 in 
the substantia nigra and hippocampus of incidental Lewy body 
disease cases and Parkinson’s disease patients. Acta Neuropathol 
Commun 2014;2:90-1.
74.  Drouin-Ouellet J, St-Amour I, Saint-Pierre M, Lamontagne-Proulx 
J, Kriz J, Barker RA, Cicchetti F. Toll-like receptor expression in 
the blood and brain of patients and a mouse model of Parkinson’s 
Disease. Int J Neuropsychopharmacol 2014; pii: pyu103.
75.  Kalinderi K, Bostantjopoulou S, Katsarou Z, Fidani L. TLR9 -1237 
T/C and TLR2 -194 to -174 del polymorphisms and the risk of 
Parkinson’s disease in the Greek population: a pilot study. Neurol 
Sci 2013;34:679-82.
76.  Noguchi E, Nishimura F, Fukai H, Kim J, Ichikawa K, Shibasaki 
M, Arinami T. An association study of asthma and total serum 
immunoglobin E levels for Toll-like receptor polymorphisms in a 
Japanese population. Clin Exp Allergy 2004;34:177-83.
77.  Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, 
Chasovskikh S, Mhyre TR, Maguire-Zeiss KA. alpha-Synuclein 
Alters Toll-Like Receptor Expression. Front Neurosci 2011;5:80.
78.  Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Lachaud CC, 
Guilliams T, Fernandez-Montesinos R, Benitez-Rondan A, Robledo 
G, Hmadcha A, Delgado M, Dobson CM, Pozo D. Preconditioning 
of Microglia by α-Synuclein Strongly Affects the Response Induced 
by Toll-like Receptor (TLR) Stimulation. PLoS One 2013;8:e79160.
79.  Frank S, Copanaki E, Burbach GJ, Müller UC, Deller T. 
Differential regulation of toll-like receptor mRNAs in amyloid 
plaque-associated brain tissue of aged APP23 transgenic mice. 
Neurosci Lett 2009;453:41-4.
80.  Jana M, Palencia CA, Pahan K. Fibrillar amyloid-beta peptides 
activate microglia via TLR2: implications for Alzheimer’s disease. 
J Immunol 2008;181:7254-62.
81.  Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 
2 acts as a natural innate immune receptor to clear amyloid 
beta 1-42 and delay the cognitive decline in a mouse model of 
Alzheimer’s disease. J Neurosci 2008;28:5784-93.
82.  Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. CD14 
and toll-like receptors 2 and 4 are required for fibrillar A{beta}-
stimulated microglial activation. J Neurosci 2009;29:11982-92.
83.  Schutze S, Loleit T, Zeretzke M, Bunkowski S, Brück W, Ribes S, Nau 
R. Additive Microglia-Mediated Neuronal Injury Caused by Amyloid-
beta and Bacterial TLR Agonists in Murine Neuron-Microglia Co-
Cultures Quantified by an Automated Image Analysis using Cognition 
Network Technology. J Alzheimers Dis 2012;31:651-57.
84.  Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N, 
Wiltfang J, Gerber J, Nau R. Amyloid beta peptide 1-40 enhances 
the action of Toll-like receptor-2 and -4 agonists but antagonizes 
Toll-like receptor-9-induced inflammation in primary mouse 
microglial cell cultures. J Neurochem 2005;94:289-98.
85.  Li H-Y, Hu J, Zhao S, Yuan ZY, Wan HJ, Lei F, Ding Y, Xing DM, 
Du LJ. Comparative Study of the Effect of Baicalin and Its Natural 
Analogs on Neurons with Oxygen and Glucose Deprivation Involving 
Innate Immune Reaction of TLR2/TNF. J Biomed Biotechnol 
2012;2012:267890.
86.  Lien E, Ingalls RR. Toll-like receptors. Crit Care Med 2002;30:S1-S11.
87.  Jang H, Boltz D, Sturm-Ramirez K, Highly pathogenic H5N1 
influenza virus can enter the central nervous system and induce 
neuroinflammation and neurodegeneration. Highly pathogenic 
H5N1 influenza virus can enter the central nervous system and 
induce neuroinflammation and neurodegeneration. Proc Natl Acad 
Sci U S A 2009;106:14063-8.
37Neuroimmunol Neuroinflammation | Volume 3 | Issue 2 | February 15, 2016
88.  Zhou L, Miranda-Saksena M, Saksena NK. Viruses and 
neurodegeneration. Virol J 2013;10:172.
89.  Wu WY, Kang KH, Chen SL, Chiu SY, Yen AM, Fann JC, Su CW, Liu 
HC, Lee CZ, Fu WM, Chen HH, Liou HH. Hepatitis C virus infection: 
a risk factor for Parkinson’s disease. J Viral Hepat 2015;22:784-91.
90.  Moulignier A, Gueguen A, Lescure FX, Ziegler M, Girard PM, 
Cardon B, Pialoux G, Molina JM, Brandel JP, Lamirel C. Does hiv 
infection alter parkinson’s disease? J Acquir Immune Defic Syndr 
2015;70:129-36.
91.  Woulfe JM, Gray MT, Gray DA, Munoz DG, Middeldorp JM. 
Hypothesis: a role for EBV-induced molecular mimicry in Parkinson’s 
disease. Parkinsonism Relat Disord 2014;20:685-94.
92.  Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning 
CJ, Häcker H, Wagner H. Endocytosed HSP60s use toll-like 
receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 
receptor signaling pathway in innate immune cells. J Biol Chem 
2001;276:31332-9.
93.  Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson 
MA, Calderwood SK. Novel signal transduction pathway utilized by 
extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J 
Biol Chem 2002;277:15028-34.
94.  Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, 
Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, 
Kwak LW. Toll-like receptor 4-dependent activation of dendritic 
cells by beta-defensin 2. Science 2002;298:1025-9.
95.  Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, 
Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel 
RC, Lu L, Hirsch EC, Hunot S, Hartmann A. Toll like receptor 4 
mediates cell death in a mouse MPTP model of Parkinson disease. 
Sci Rep 2013;3:1393.
96.  Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. 
Toll-like receptor 4 promotes alpha-synuclein clearance and survival 
of nigral dopaminergic neurons. Am J Pathol 2011;179:954-63.
97.  Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, 
Lee VM. Neuroinflammation and oxidation/nitration of alpha-
synuclein linked to dopaminergic neurodegeneration. J Neurosci 
2008;28:7687-98.
98.  Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg 
PA, Volpe JJ, Vartanian T. Activation of innate immunity in the CNS 
triggers neurodegeneration through a Toll-like receptor 4-dependent 
pathway. Proc Natl Acad Sci U S A 2003;100:8514-9.
99.  Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode 
B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K. Role 
of the toll-like receptor 4 in neuroinflammation in Alzheimer’s 
disease. Cell Physiol Biochem 2007;20:947-956.
100. Minoretti P, Gazzaruso C, Vito CD, Emanuele E, Bianchi M, Coen 
E, Reino M, Geroldi D. Effect of the functional toll-like receptor 4 
Asp299Gly polymorphism on susceptibility to late-onset Alzheimer’s 
disease. Neurosci Lett 2006;391:147-9.
101.  Jin J-J, Kim H-D, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 
4-dependent upregulation of cytokines in a transgenic mouse model 
of Alzheimer’s disease. J Neuroinflammation 2008;5:3006-19.
102. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. Role of 
toll-like receptor signalling in Abeta uptake and clearance. Brain 
2006;129:3006-19.
103. Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan 
D, Gordon MN. Time-dependent reduction in Aβ levels after 
intracranial LPS administration in APP transgenic mice. Exp Neurol 
2004;190:245-53.
104. Rosenzweig HL, Lessov NS, Henshall DC, Minami M, Simon RP, 
Stenzel-Poore MP. Endotoxin preconditioning prevents cellular 
inflammatory response during ischemic neuroprotection in mice. 
Stroke 2004;35:2576-81.
105. De Paola M, Mariani A, Bigini P, Peviani M, Ferrara G, Molteni M, 
Gemma S, Veglianese P, Castellaneta V, Boldrin V, Rossetti C, 
Chiabrando C, Forloni G, Mennini T, Fanelli R. Neuroprotective effects 
of Toll-like receptor 4 antagonism in spinal cord cultures and in a mouse 
model of motor neuron degeneration. Mol Med 2012;18:971-81.
106. Zeng KW, Zhang T, Fu H, Liu GX, Wang XM. Schisandrin B 
exerts anti-neuroinflammatory activity by inhibiting the Toll-like 
receptor 4-dependent MyD88/IKK/NF-kappaB signaling pathway 
in lipopolysaccharide-induced microglia. Eur J Pharmacol 
2012;692:29-37.
107.  Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: 
role of inflammatory cells. J Leukoc Biol 2010;87:779-89.
108. Ohto U, Tanji H, Shimizu T. Structure and function of toll-like 
receptor 8. Microbes Infect 2014;16:273-82.
109. Brea D, Sobrino T, Rodríguez-Yáñez M, Ramos-Cabrer P, Agulla 
J, Rodríguez-González R, Campos F, Blanco M, Castillo J. Toll-
like receptors 7 and 8 expression is associated with poor outcome 
and greater inflammatory response in acute ischemic stroke. Clin 
Immunol 2011;139:193-8.
110.  Tang SC, Yeh SJ, Li YI, Wang YC, Baik SH, Santro T, Widiapradja A, 
Manzanero S, Sobey CG, Jo DG, Arumugam TV, Jeng JS. Evidence 
for a detrimental role of TLR8 in ischemic stroke. Exp Neurol 
2013;250:341-347.
111.  Piersanti S, Astrologo L, Licursi V, Costa R, Roncaglia E, Gennetier 
A, Ibanes S, Chillon M, Negri R, Tagliafico E, Kremer EJ, Saggio 
I. Differentiated neuroprogenitor cells incubated with human or 
canine adenovirus, or lentiviral vectors have distinct transcriptome 
profiles. PLoS One 2013;8:e69808.
112. Jang H, Boltz DA, Webster RG, Smeyne RJ. Viral parkinsonism. 
Biochim Biophys Acta (BBA)-Molecular Basis Dis 2009;1792:714-21.
113. Diogenes A, Ferraz CC, Akopian AN, Henry MA, Hargreaves KM. LPS 
sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. 
J Dent Res 2011;90:759-64.
